Non-Substantial Change Request _Crosswalk

Att2_EIP2023_NonSub_Crosswalk_OCT2022.docx

[NCEZID] Emerging Infections Program

Non-Substantial Change Request _Crosswalk

OMB: 0920-0978

Document [docx]
Download: docx | pdf

Cross walk - 2023 form changes




FoodNet


  1. FoodNet Active Surveillance Data Elements List – Attachment #3

Refer to Attachment #3 - Changes are highlighted in Yellow

  1. FoodNet Hemolytic Uremic Syndrome Data Elements List – Attachment #4

Refer to Attachment #4 - Changes are highlighted in Yellow

  1. Diagnostic Laboratory Practices and Volume Elements List – Attachment #5

Refer to Attachment #5 – Changes are highlighted in Yellow


FluSurv-Net


  1. FluSurv-NET Influenza Surveillance Project Case Report Form– Attachment #6


Question on 2021-22 Form

Question on 2022-23 Form

C9. Race:

  • White

  • Black or African American

  • Asian/Pacific Islander

  • American Indian or Alaska Native

  • Multiracial

  • Not specified


C8. Race (select all that apply):

  • White

  • Black or African American

  • Asian

  • Native Hawaiian or Other Pacific Islander

  • American Indian or Alaska Native

  • Multiracial, not otherwise specified

  • Not specified


C2. Admission Type

  • Hospitalization

  • Observation only

Deleted question C2 regarding Admission Type

HIj. Pregnant

  • Yes

  • No/Unknown

C12. Pregnant (15-49 years of age only):

  • Yes

  • No/Unknown

  • Not applicable (Male)

This question was not present

H 10. Mental Health Conditions [] Yes [] No/Unknown

  • Anxiety disorder

  • Bipolar disorder

  • Depression

  • Schizophrenia spectrum disorder

I1. Were any culture tests performed within 7 days of admission? (for patients that died in the hospital, include culture tests performed either 1) within 7 days of admission, 2) within 3 days prior to death, or 3) within 24 hours after death?

  • Yes

  • No

  • Unknown

I1 Were any culture tests performed within 3 days prior to or 3 days following admission

  • Yes

  • No

  • Unknown

J1. Was the patient tested for any viral pathogen within 14 days prior to or within 7 days of admission?

  • Yes

  • No

  • Unknown

J1. Was the patient tested for any viral pathogen within 14 days prior to or within <= 3 days after admission?

  • Yes

  • No

Unknown

I2. If yes, was there a positive culture for aspergillus, mucormycosis, or a bacterial pathogen?

  • Yes

  • No

  • Unknown

I2c. Result of culture

  • Positive

  • Negative

  • Unknown

I2a. If yes, specify pathogen

  • Aspergillus (fungus)

  • Mucormycosis (fungus)

  • Bacteria, specify

I2d. If positive, what pathogen was identified?

  • Bacteria, specify

  • Aspergillus (fungus)

  • Mucormycosis (fungus)

K2C. Treatment End Date


  • Date or Unknown

This question was deleted

M1. Did the patient have any of the following new diagnoses at discharge (select all that apply)

M1. Did the patient have any of the following new diagnoses at discharge (select all that apply)


  • All diagnoses that were previously collected are also collected this season

  • Mucormycosis was added as a new diagnosis




  1. FluSurv-NET/RSV Laboratory Survey– Attachment #7


Question on 2021-22 form

Question on 2022-23 form

4a. Select the kit names for the rapid influenza diagnostic tests performed or planned to be used at the laboratory (check all that apply)




4a. Select the kit names for the rapid influenza diagnostic tests performed or planned to be used at the laboratory (check all that apply)


5A. Select Kit names for all molecular assays performed or planned to be used at the laboratory (check all that apply)


5A. Select Kit names for all molecular assays performed or planned to be used at the laboratory (check all that apply)

5B If more than one kit is selected above, please select the one kit name that is (or will be) used most frequently for molecular assay at the laboratory during the current influenza season:

5B If more than one kit is selected above, please select the one kit name that is (or will be) used most frequently for molecular assay at the laboratory during the current influenza season:

6A. Which influenza test method does the laboratory perform most frequently for pediatric patients (0-17 years)?



6A. Which influenza test method does the laboratory perform most frequently for pediatric patients (0-17 years)?


6B. Which influenza test method does the laboratory perform most frequently for adult patients (aged >= 18 years)?



6B. Which influenza test method does the laboratory perform most frequently for adult patients (aged >= 18 years)?


7. Based on tests that were performed during the 2021-2022 influenza season, approximately what percent of the time are each of these test types used to test for flu overall




7. Based on tests that were performed during the 2021-2022 influenza season, approximately what percent of the time are each of these test types used to test for flu overall







HAIC


  1. HAIC: Invasive Methicillin-resistant Staphylococcus aureus (MRSA) Infection Case Report Form (Attachment #9)



2022 CRF Question

Changes to the 2023 CRF Question


2a. Planning region

34a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) on or in the year before the DISC?

Yes □ No □ Unknown

34a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) on or in the 90 days before the DISC?

Yes □ No □ Unknown

34a.

IF YES, complete below for MOST RECENT positive test for SARS-CoV-2 on or in the year before the DISC:

Specimen collection date:

__-__-____ □ Unknown

Test type:

Antigen

Molecular assay

Serology

Method unknown

Other (specify): ________

34a.

Specimen collection dates for positive tests in the 90 days before or day of DISC:

First positive test: __-__-____ □ Unknown

Most recent positive test: __-__-____ □ Unknown



34a. COVIDNET Case ID: _____________

NNDSS IDs (please provide at least one of the following when applicable):

CDC 2019 NCOV ID: _____________

Local case ID: _____________

Local record ID: _____________

State case identifier: _____________

Legacy case identifier: _____________

34a. COVIDNET Case ID: _____________





  1. HAIC: Invasive Methicillin-sensitive Staphylococcus aureus (MSSA) Infection Case Report Form (Attachment #10)


2022 CRF Question

Changes to the 2023 CRF Question


2a. Planning Region

34a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) on or in the year before the DISC?

Yes □ No □ Unknown

34a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) on or in the 90 days before the DISC?

Yes □ No □ Unknown

34a.

IF YES, complete below for MOST RECENT positive test for SARS-CoV-2 on or in the year before the DISC:

Specimen collection date:

__-__-____ □ Unknown

Test type:

Antigen

Molecular assay

Serology

Method unknown

Other (specify): ________

34a.

Specimen collection dates for positive tests in the 90 days before or day of DISC:

First positive test: __-__-____ □ Unknown

Most recent positive test: __-__-____ □ Unknown



34a. COVIDNET Case ID: _____________

NNDSS IDs (please provide at least one of the following when applicable):

CDC 2019 NCOV ID: _____________

Local case ID: _____________

Local record ID: _____________

State case identifier: _____________

Legacy case identifier: _____________

34a. COVIDNET Case ID: _____________





  1. HAIC: Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales / Invasive Escherichia coli (iEC) Multi-site Gram-Negative Surveillance Initiative (MuGSI) Case Report Form (CRF) (Attachment #11)


Question on original 2022 form

Question on 2023 form

Description of change

24a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) in the year before or day of the DISC?

ð Yes

ð No

ð Unknown

24a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, antigen, or other viral test, excluding serology) in the 90 days before or day of the DISC?

ð Yes

ð No

ð Unknown

i. Updated the text for the question

24b. If yes, complete the table below for the most recent positive SARS-CoV-2 test in the year before or day of the DISC:



Specimen collection date

Test type

__/__/____

Unknown

Molecular assay

Antigen

Serology

Unknown

Other (specify):___________




24b. Specimen collection dates for positive tests in the 90 days before or day of DISC:




First positive test:

__/__/____ or

Date unknown

Most recent positive test:

__/__/____ or

Date unknown


i. Updated the text for the question

ii. Removed the test type

iii. Added specimen collection date for first and most recent positive test


  1. HAIC: Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Acinetobacter baumannii (CRAB) Multi-site Gram-Negative Surveillance Initiative (MuGSI) Case Report Form (CRF) (Attachment #12)

Question on original 2022 form

Question on 2023 form

Description of change

2022 Carbapenem Resistant Enterobacteriaceae (CRE)/ Carbapenem Resistant A. baumannii

(CRAB) Multi-site Gram-Negative Surveillance Initiative (MuGSI)

Healthcare-Associated Infections Community Interface (HAIC) Case Report

2023 Carbapenem Resistant Enterobacterales (CRE)/ Carbapenem Resistant A. baumannii

(CRAB) Multi-site Gram-Negative Surveillance Initiative (MuGSI)

Healthcare-Associated Infections Community Interface (HAIC) Case Report

I. Updated the year to 2023

II. Updated Enterobacteriaceae to Enterobacterales

Q2. County

Q2a. County

I. Updated the question number


Q2b. Planning region

I. Added question

23b. Risk factors in the 7 days before the DISC:

ð Non-invasive positive pressure ventilation (CPAP or BiPAP) at any time in the

7 calendar days before the DISC

ð Nebulizer treatment at any time in the 7 calendar days before the DISC

ð Mechanical ventilation at any time in the 7 calendar days before the DISC

23b. Risk factors in the 7 days before the DISC:

ð Non-invasive positive pressure ventilation (CPAP or BiPAP) at any time in the

7 calendar days before the DISC

ð Nebulizer treatment at any time in the 7 calendar days before the DISC

ð Mechanical ventilation at any time in the 7 calendar days before the DISC

ð None

I. Added a checkbox for “none”


24a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) in the year before or day of the DISC?

ð Yes

ð No

ð Unknown

24a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, antigen, or other viral test, excluding serology) in the 90 days before or day of the DISC?

ð Yes

ð No

ð Unknown

i. Updated the text for the question

24b. If yes, complete the table below for the most recent positive SARS-CoV-2 test in the year before or day of the DISC:



Specimen collection date

Test type

__/__/____

Unknown

Molecular assay

Antigen

Serology

Unknown

Other (specify):___________




24b. Specimen collection dates for positive tests in the 90 days before or day of DISC:




First positive test:

__/__/____ or

Date unknown

Most recent positive test:

__/__/____ or

Date unknown


i. Updated the text for the question

ii. Removed the test type

iii. Added specimen collection date for first and most recent positive test




  1. HAIC: CDI Case Report and Treatment Form (Attachment #13)


2022 CRF

2023 CRF

Changes

6. County

6a. County

changed question number

[question not on CRF]

6b. Planning region

new question

36. Previous unique CDI episode

38. Previous unique CDI episode

changed question number

37. Any recurrent C. diff+ episodes following this incident C. diff+ episode?

39. Any recurrent C. diff+ episodes following this incident C. diff+ episode?

changed question number

37a. If YES, Date of first
recurrent specimen

39a. If YES, Date of first
recurrent specimen

changed question number

38. CRF status

40. CRF status

changed question number

39. Initials of SO

41. Initials of SO

changed question number

40. Date of abstraction

42. Date of abstraction

changed question number

41. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) in the year before or day of the DISC?

36. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, antigen, or other viral test; excluding serology) in the 90 days before or day of the DISC?

changed question number, changed time period, changed tests under consideration

[question not on CRF]

36a. [Specimen collection dates for positive tests in the 90 days before or day of DISC]
First positive test: __ __ / __ __ / __ __ __ __ or □ Date unknown

new question

41a.1 [If YES, complete below for most recent positive test for SARS CoV-2 in the year before or date of the DISC] - Specimen collection date

36b. [Specimen collection dates for positive tests in the 90 days before or day of DISC]
Most recent positive test: __ __ / __ __ / __ __ __ __ or □ Date unknown

Reworded, changed time period

41a.2 [If YES, complete below for most recent positive test for SARS CoV-2 in the year before or date of the DISC] - Test type

[question not on CRF]

Removed question

42a. COVID-NET Case ID

37. COVID-NET Case ID

changed question number

42b. NNDSS IDs

[question not on CRF]

Removed question



  1. HAIC: CDI Annual Surveillance Officers Survey (Attachment #14)


Existing question

Modified question

2. In 2021, did any laboratories drop out of participation?

2. In 2022, did any laboratories drop out of participation?

(changed year to 2022 to reflect change in survey year)

3. In 2021, did you identify any additional laboratories inside or outside of your catchment area which identify C.diff assays from persons who are residents of your catchment area?

3. In 2022, did you identify any additional laboratories inside or outside of your catchment area which identify C.diff assays from persons who are residents of your catchment area?

(changed year to 2022 to reflect change in survey year)

10. Did your site complete a physician/outpatient provider survey in 2021?

10. Did your site complete a physician/outpatient provider survey in 2022?

(changed year to 2022 to reflect change in survey year)

13. For each facility that treated a case in 2021, please provide the following

13. For each facility that treated a case in 2022, please provide the following

(changed year to 2022 to reflect change in survey year)




  1. HAIC: Annual Survey of Laboratory Testing Practices for C. difficile Infections (Attachment #15)



2022

2023

Changes

Was this a new laboratory in 2021?

Was this a new laboratory in 2022?

Changed year to 2022 to reflect change in survey year

Did this lab participate in surveillance in 2021?

Did this lab participate in surveillance in 2022?

Changed year to 2022 to reflect change in survey year

How often did you receive line lists from this lab in 2021?

How often did you receive line lists from this lab in 2022?

Changed year to 2022 to reflect change in survey year

How did you receive line lists from this lab in 2021?

How did you receive line lists from this lab in 2022?

Changed year to 2022 to reflect change in survey year

Did you receive specimens from this lab in 2021?

Did you receive specimens from this lab in 2022?

Changed year to 2022 to reflect change in survey year

Was this lab audited in 2021?

Was this lab audited in 2022?

Changed year to 2022 to reflect change in survey year

Types of facilities in your catchment area served by this lab in 2021

Types of facilities in your catchment area served by this lab in 2022

Changed year to 2022 to reflect change in survey year

1. Did your laboratory ever send specimens off-site for Clostridioides difficile testing in 2021?

1. Did your laboratory ever send specimens off-site for Clostridioides difficile testing in 2022?

Changed year to 2022 to reflect change in survey year

2. What type and order of testing was routinely used by your laboratory in standard testing for C. difficile on December 31, 2021?
1st line of testing: ________ 2nd line of testing: ________ 3rd line of testing: ________

[question not on survey]

Removed question

2a. Which specimens were used during your 2nd line of testing?

[question not on survey]

Removed question

2b. Which specimens were used during your 3rd line of testing?

[question not on survey]

Removed question

2c. Did your laboratory perform any onsite testing for C. difficile outside of your normal testing algorithm in 2021?

[question not on survey]

Removed question

[question not on survey]

[Question 2a is a table with this heading] Which testing method(s) for Clostridioides difficile (C. difficile) did your laboratory perform in 2022? (Choose all that apply. Include testing methods used for only part of the year or for only a specific subset of specimens, if applicable)

Added table of questions

[question not on survey]

Did your laboratory use this testing method for Clostridioides difficile (C. difficile) in 2022?

Added table of questions

[question not on survey]

[For each testing method selected] Specify when you used this test (e.g. at provider request, for outpatients, for inpatients with a length of stay > 3 days, for every specimen received)

Added table of questions

[question not on survey]

[For each testing method selected] Did you use this testing method in this way for all of 2022?

Added table of questions

[question not on survey]

[For each testing method selected] What date did you change?

Added table of questions

[question not on survey]

[For each testing method selected] What test did you use in this situation before this date?

Added table of questions

3a. Which EIA test kit was used by your laboratory in 2021?

3a. Which EIA test kit was used by your laboratory in 2022?

Changed year to 2022 to reflect change in survey year

3b. Which Nucleic Acid Amplification test was used by your laboratory in 2021?

3b. Which Nucleic Acid Amplification test was used by your laboratory in 2022?

Changed year to 2022 to reflect change in survey year

4a. If your laboratory used a multiplexed molecular diagnostic (e.g., Biofire Filmarray GI Panel, Luminex xTAG GPP) to test for several GI pathogens in 2021, did your laboratory suppress the C. difficile result so that clinicians could not see it?

4a. If your laboratory used a multiplexed molecular diagnostic (e.g., Biofire Filmarray GI Panel, Luminex xTAG GPP) to test for several GI pathogens in 2022, did your laboratory suppress the C. difficile result so that clinicians could not see it?

Changed year to 2022 to reflect change in survey year

4b. If your laboratory used a multiplexed diagnostic in 2022 and the result was suppressed, where does the suppression occur?

4b. If your laboratory used a multiplexed diagnostic in 2022 and the result was suppressed, where does the suppression occur?

Changed year to 2022 to reflect change in survey year

5a. If your laboratory used a nucleic acid amplification test (NAAT) (e.g., Cepheid Xpert C. difficile) as first line testing followed by a toxin EIA test (whenever NAAT result is positive) in 2022, did your laboratory suppress the positive NAAT result so that clinicians could not see it?

5a. If your laboratory used a nucleic acid amplification test (NAAT) (e.g., Cepheid Xpert C. difficile) as first line testing followed by a toxin EIA test (whenever NAAT result is positive) in 2022, did your laboratory suppress the positive NAAT result so that clinicians could not see it?

Changed year to 2022 to reflect change in survey year

5b. If your laboratory used NAAT as first line testing followed by confirmatory toxin EIA testing in 2022, and both the NAAT and toxin EIA results were released to the clinician, did your laboratory provide any comments to help the clinician interpret the test results (e.g., NAAT-positive only result might represent colonization, etc.)?

5b. If your laboratory used NAAT as first line testing followed by confirmatory toxin EIA testing in 2022, and both the NAAT and toxin EIA results were released to the clinician, did your laboratory provide any comments to help the clinician interpret the test results (e.g., NAAT-positive only result might represent colonization, etc.)?

Changed year to 2022 to reflect change in survey year

6. What are the LOINC or internal testing codes associated with the tests your lab used in 2022 (e.g. LOINC codes 13957-6, 34713-8, or 54067-4)?

6. What are the LOINC or internal testing codes associated with the tests your lab used in 2022 (e.g. LOINC codes 13957-6, 34713-8, or 54067-4)?

Changed year to 2022 to reflect change in survey year

7a. In 2021, did your laboratory experience any shortages in supplies, reagents, and/or test kits for performing C. difficile testing (e.g., NAAT or EIA reagents, swabs)?

[question not on survey]

Removed question

7b. If your laboratory experienced a supply shortage for C. difficile testing in 2021, how did the shortage affect your laboratory’s ability to perform C. difficile testing?

[question not on survey]

Removed question

7c. In 2021, did your laboratory experience a high demand for COVID-19 testing that limited the availability of staff (e.g., reduced staffing or work time) or the use of equipment to perform C. difficile testing?

[question not on survey]

Removed question

8. Did your lab testing algorithm for C. difficile change between January 1, 2021 and December 31, 2021?

[question not on survey]

Removed question

What date did this change occur? ______ / ______ / _____

[question not on survey]

Removed question

8a. What was the previous type and order of testing performed by your lab in 2021 before it changed its testing algorithm?
1st line of testing: ________ 2nd line of testing: ________ 3rd line of testing: ________

[question not on survey]

Removed question

8b. Which specimens were used during your 2nd line of testing?

[question not on survey]

Removed question

8c. Which specimens were used during your 3rd line of testing?

[question not on survey]

Removed question

9. Did your lab have a policy to reject stool specimens for C. difficile testing in 2021? (Read all options. Check all that apply)
□ Yes, when stools are formed (formed stools are defined as stools that do NOT take the shape of the container)
□ Yes, if there is a stool specimen already positive within 24 hrs of a new stool specimen
□ Yes, if there is a stool specimen already positive within 48 hrs of a new stool specimen
□ Yes, if there is a stool specimen that tested negative for C. difficile within 48 hours of a new stool specimen
□ Yes, will not accept more than one stool specimen in a 24 hr period
□ No rejection policy
□ Other rejection policies
Specify other rejection policy: __________________________

7. Did your lab have a policy to reject stool specimens for C. difficile testing in 2022? (Read all options. Check all that apply, even if it only applies sometimes)
□ Yes, when stools are formed (formed stools are defined as stools that do NOT take the shape of the container)
□ Yes, if there was a positive stool specimen recently (e.g. within 24 hours, within 7 days)
□ Yes, if there was a negative stool specimen recently (e.g. within 24 hours, within 7 days)
□ Yes, will not accept more than one stool specimen in a 24 hr period
□ Yes, if patient is on a specific medication (e.g. laxatives)
□ No rejection policy
□ Other rejection policies
Specify other rejection policy: __________________________

Changed year to 2022 to reflect change in survey year, simplified response options, renumbered question

9a. Did your rejection policy for stool specimens change between January 1, 2021 and December 31, 2021?

7a. Did your rejection policy for stool specimens change between January 1, 2022 and December 31, 2022?

Changed year to 2022 to reflect change in survey year, renumbered question

10. How many stool samples did you test for C. difficile each month in 2021?

8. How many stool samples did you test for C. difficile each month in 2022?

Changed year to 2022 to reflect change in survey year, renumbered question





  1. HAIC: Candidemia Case Report (Attachment #16)



2022 CRF Question

2023 CRF Question

CANDIDEMIA 2022 CASE REPORT FORM (header)


CANDIDEMIA 2023 CASE REPORT FORM (header)

(changed year)

Version: Short Form 2022, Last Updated: 07/17/2021 (footnotes)


Version: Short Form 2023, Last Updated: 07/29/2022 (footnotes)

(changed year and date)

23. Incident Specimen Collection Site (check all that apply):

Blood, Central line

Blood, Peripheral stick

Blood, not specified

Other (specify):____________

Unknown

(removed question)

Question 24-25 

(changed number by 1)

New Question

25. Did the patient have a culture-independent diagnostic test (CIDT) for Candida, (eg: T2), on the day of or in the 6 days before the DISC?

1 Yes 0 No 9 Unknown



25a. If yes, test type: ______________________

25b. Result: ______________________________



(new question)

30. Infection with Clostridioides difficile on the day of or in the 89 days before or 29 days after the DISC:

1 Yes 0 No 9 Unknown

30a. If yes, date of first C. diff diagnosis: ___ ___ - ___ ___ - ___ ___ ___ ___ Unknown

(removed question)

31. Did the patient have any of the following types of infection/colonization related to their Candida infection? (check all that apply):

None Unknown

Abdominal

Hepatobiliary or pancreatic

GI tract

Abscess (specify): _________

Peritonitis/peritoneal fluid

Splenic

Candiduria

Esophagitis

Oral/thrush

Osteomyelitis

Skin lesions/wounds

Pulmonary

Abscess

Respiratory specimen with Candida

CNS involvement (meningitis, brain abscess)

Eyes (endophthalmitis or chorioretinitis)

Endocarditis

Septic emboli (specify location): _________

Other (specify): __________


30. Did the patient have any of the following types of infection related to their Candida infection? (check all that apply):

None Unknown

Abdominal infection

Hepatobiliary or pancreatic

Abscess (specify): _________

Peritonitis/peritoneal fluid

Splenic

Urinary tract infection

Esophagitis

Oral/thrush

Osteomyelitis

Skin/wound infection

Pulmonary infection

Abscess

CNS infection (meningitis, brain abscess)

Eyes

Endophthalmitis

Chorioretinitis

Endocarditis

Septic emboli (specify location): _________

Other (specify): __________

(changed question number, question wording, response options)

Question 32-34 


(changed number by 1)

35. Did the patient receive invasive mechanical ventilation in the 30 days before the DISC, not including the DISC?

1 Yes 0 No 9 Unknown

(removed question)

Question 36-37a


(changed number by 2)

38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization?

(Check all that apply):

None

Unknown

B37 (candidiasis)

Specify sub-code: ___________________

Specify sub-code: ___________________

P37.5 (neonatal candidiasis)

B48 (other mycoses, not classified elsewhere)

B49 (unspecified mycoses)

T80.211 (BSI due to central venous catheter)

A41.9 (sepsis, unspecified organism)

R65.2 (severe sepsis)

Other Candida-related code

Specify code: ___________________

36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization?

(Check all that apply):

None

Unknown

Not applicable (i.e., patient not hospitalized)

B37 (candidiasis)

Specify sub-code: ___________________

Specify sub-code: ___________________

P37.5 (neonatal candidiasis)

B48 (other mycoses, not classified elsewhere)

B49 (unspecified mycoses)

T80.211 (BSI due to central venous catheter)

A41.9 (sepsis, unspecified organism)

R65.2 (severe sepsis)

Other Candida-related code

Specify code: ___________________



(changed question number, added check box option for not applicable)

Question 39-44


(changed number by 2)

45. Other Substances (Check all that apply):

Mode of Delivery (Check all that apply):

IDU Skin popping Non-IDU Unknown

IDU Skin popping Non-IDU Unknown

IDU Skin popping Non-IDU Unknown

IDU Skin popping Non-IDU Unknown

IDU Skin popping Non-IDU Unknown

IDU Skin popping Non-IDU Unknown

IDU Skin popping Non-IDU Unknown

IDU Skin popping Non-IDU Unknown


43. Other Substances (Check all that apply):

Mode of Delivery (Check all that apply):

IDU Non-IDU Unknown

IDU Non-IDU Unknown

IDU Non-IDU Unknown

IDU Non-IDU Unknown

IDU Non-IDU Unknown

IDU Non-IDU Unknown

IDU Non-IDU Unknown

IDU Non-IDU Unknown



(changed question number, removed “Skin popping” as an option)

Question 46-50


(changed number by 2)

New Question

49. Did the patient have any ostomies of the gastrointestinal tract including ileostomy, colostomy, etc. in the 30 calendar days before, not including the DISC?

1 Yes 0 No 9 Unknown

Question 51-53a


(changed number by 2)

53b. Were all CVCs removed or changed on the day of or in the 6 days after the DISC?

1 Yes

2 No

3 CVC removed, but can’t find dates

5 Died or discharged before indwelling catheter replaced

9 Unknown


52b. Were all CVCs removed or changed in the 2 days before or in the 6 days after the DISC?

1 Yes

2 No

3 CVC removed, but can’t find dates

5 Died or discharged before indwelling catheter replaced

9 Unknown



(changed question number and question wording)

Question 54-55


(changed number by 1)

56. Did the patient have a positive SARS-CoV-2 test result (molecular assay, serology, or other confirmatory test) from a specimen collected in the 90 days before the DISC or on the DISC?

1 Yes

0 No

9 Unknown

55. Did the patient have a positive SARS-CoV-2 test result (molecular assay, antigen, or other confirmatory test, excluding serology) from a specimen collected in the 90 days before the DISC or on the DISC?

1 Yes

0 No

9 Unknown



(changed question number and question wording)

Question 56a-58


(changed number by 1)

58a. If yes, what was the reason steroids were administered? (check all that apply)

Steroid(s) given as an outpatient medication

Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC

Steroid(s) given as part of treatment/management for COVID-19


57a. If yes, what was the reason steroids were administered? (check all that apply)

Steroid(s) given as an outpatient medication

Steroid(s) given, prior to Candida DISC, during hospitalization associated with candidemia episode

Steroid(s) given as part of treatment/management for COVID-19

None of the above



(changed question number and response wording, added check box for additional response option)

Question 59

(changed number by 1)

60. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? ­­­­­(check all that apply)

None Tocilizumab Sarilumab Baricitinib Unknown



60a. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19?

1 Yes 0 No 9 Unknown

(removed questions)

Question 61-65

(changed number by 2)

New Question

64. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC?

1 Yes 0 No 9 Unknown

New Question

65. Did the patient have a dilated fundoscopic eye exam on the day of or 13 days after the DISC?

1 Yes 0 No 9 Unknown






  1. HAIC: Laboratory Testing Practices for Candidemia Questionnaire (Attachment #17)



2022 Lab Survey Question

2023 Lab Survey Question

2022 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE (header)




2023 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE (header)



(changed year)

  1. What kind of laboratory is this facility? (select one)



Hospital laboratory

Commercial laboratory (Quest, etc.)

Other (specify) ______________________

Unknown


  1. What kind of laboratory is this? (select one)




Hospital laboratory

Commercial laboratory (Quest, etc.)

Other (specify) ______________________

Unknown



(changed question wording to remove “facility”) 

  1. Does this facility ever receive blood cultures from nursing homes or other long term care facilities?

Yes

No

Unknown


  1. Does this laboratory ever receive blood cultures from nursing homes or other long term care facilities?

Yes

No

Unknown



(changed question wording to replace “facility” with “laboratory”) 

  1. What is the approximate volume of any type of fungal cultures performed annually in your laboratory?

Specify number: ______________ Unknown

  1. What is the approximate volume of fungal cultures ordered and performed annually in your laboratory for any specimen type?

Specify number: ______________ Unknown



(changed question wording) 

  1. What is the approximate volume of fungal cultures from blood performed annually in your laboratory?

Specify number: ______________ Unknown

  1. What is the approximate volume of fungal blood cultures ordered and performed annually in your laboratory?

Specify number: ______________ Unknown



(changed question wording) 

  1. Does this laboratory offer yeast identification either onsite or sent to another laboratory?

Yes

No (-------- If No, SKIP TO QUESTION 15 --------)

Unknown (is there another laboratory staff member who can assist with the questionnaire?)


  1. Does this laboratory offer yeast identification (either onsite or sent to another laboratory)?

Yes

No (-------- If No, SKIP TO QUESTION 18 --------)

Unknown (is there another laboratory staff member who can assist with the questionnaire?)



(added paratheses to question wording, updated skip logic in response options) 

  1. Does this laboratory routinely use Chromagar for the identification or differentiation of Candida isolates?

Yes

No

Unknown


  1. Does this laboratory routinely use chromogenic agar for the identification or differentiation of Candida isolates?

Yes

No

Unknown



(changed question wording to replace “Chromagar” with “chromogenic agar”) 

  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Blood isolates

Yes, reflexively

Yes, with clinician order

No

Unknown


  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Blood isolates

Yes, always

Yes, with clinician order

No

Unknown



(changed first response option wording) 

  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Other normally sterile body site isolates

Yes, reflexively

Yes, with clinician order

No

Unknown


  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Other normally sterile body site isolates

Yes, always

Yes, with clinician order

No

Unknown



(changed first response option wording) 

  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Abdominal isolates

Yes, reflexively

Yes, with clinician order

No

Unknown


  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Abdominal isolates

Yes, always

Yes, with clinician order

No

Unknown



(changed first response option wording) 

  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Respiratory isolates

Yes, reflexively

Yes, with clinician order

No

Unknown


  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Respiratory isolates

Yes, always

Yes, with clinician order

No

Unknown



(changed first response option wording) 

  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Urine isolates

Yes, reflexively

Yes, with clinician order

No

Unknown


  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Urine isolates

Yes, always

Yes, with clinician order

No

Unknown



(changed first response option wording) 

  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Other (specify) _________________

Yes, reflexively

Yes, with clinician order

No

Unknown


  1. Species-level identification is performed for Candida spp. isolated from which of the following?



  1. Other (specify) _________________

Yes, always

Yes, with clinician order

No

Unknown



(changed first response option wording) 

  1. Does this laboratory employ culture-independent diagnostic tests (CIDT) to identify Candida from blood specimens?

Yes (got to q14)

No (got to q17)

Unknown


  1. Does this laboratory employ culture-independent diagnostic tests (CIDTs) to identify Candida from blood specimens?

Yes (go to Q14)

No (go to Q17)

Unknown



(changed question wording to update CIDT abbreviation, changed formatting of skip logic in the response wording) 

14) Does this laboratory employ the T2Candida Panel to identify Candida from blood specimens?

Yes (got to 12a)

No (go to 13)

Unknown


14) Does this laboratory employ the T2Candida Panel to identify Candida from blood specimens?

Yes (go to Q14a)

No (go to Q15)

Unknown



(changed formatting of skip logic in the response wording) 

14) Does this laboratory employ the T2Candida Panel to identify Candida from blood specimens?

  1. If Yes, does this lab culture blood if you get a positive result on T2Candida Panel?



Yes, reflexively

Yes, with a clinical order

No

Unknown


14) Does this laboratory employ the T2Candida Panel to identify Candida from blood specimens?

  1. If Yes and you get a positive result on T2Candida Panel, does this lab culture the blood to obtain an isolate?

Yes, always

Yes, with a clinical order

No

Unknown



(changed question wording, changed first response option wording) 

15) Does this laboratory employ the BioFire (FilmArray) to identify Candida from blood specimens?

Yes (go to 15a)

No (go to 16)

Unknown


15) Does this laboratory employ the BioFire (FilmArray) to identify Candida from blood specimens?

Yes (go to Q15a)

No (go to Q16)

Unknown



(changed formatting of skip logic in the response wording) 

15) Does this laboratory employ the BioFire (FilmArray) to identify Candida from blood specimens?

  1. If Yes, does this lab reflexively culture blood if you get a positive result on BioFire?



Yes, reflexively

Yes, with a clinical order

No

Unknown


15) Does this laboratory employ the BioFire (FilmArray) to identify Candida from blood specimens?

  1. If Yes and you get a positive result on BioFire, does this lab culture the blood to obtain an isolate?



Yes, always

Yes, with a clinical order

No

Unknown



(changed question wording, changed first response option wording) 

  1. Where is antifungal susceptibility testing (AFST) done? (check the most applicable)

On-site, in the laboratory

Sent to commercial lab

Sent to affiliated hospital lab

Sent to other local/regional, non-affiliated reference or public health laboratory

Other ______________________________

Unknown


  1. Where is antifungal susceptibility testing (AFST) done? (check the most applicable)

On-site, in the laboratory (go to Q20)

Sent to commercial lab (-------- If not an on-site laboratory, QUESTIONNAIRE COMPLETE --------)

Sent to affiliated hospital lab

Sent to other local/regional, non-affiliated reference or public health laboratory

Other ______________________________

Unknown



(changed skip logic in the response wording) 

21) What methods are used for AFST? (check all that apply)

Non-commercial broth microdilution

YeastOne

E test

Vitek

Other ______________________________

Unknown




21) What methods are used for AFST, excluding Amphotericin B? (check all that apply)

Broth microdilution with laboratory developed plates

YeastOne (Thermo Scientific™ Sensititre

Gradient diffusion (E test)

Vitek (bioMerieux)

Other ______________________________

Unknown



(changed question wording to specify all antifungals except Amp B, changed response option wording) 

  1. If you use Vitek for AFST, what Candida species do you test with it? (check all that apply)

C. albicans

C. glabrata

C. parapsilosis

Other Candida spp.

(removed question)

New question


22) What methods are used for AFST of Amphotericin B? (check all that apply)

Broth microdilution with laboratory developed plates

YeastOne (Thermo Scientific™ Sensititre

Gradient diffusion (E test)

Vitek (bioMerieux)

Other ______________________________

Unknown



(new question)

  1. How does this laboratory meet proficiency testing requirements for antifungal susceptibility testing, if performed?

Commercial provider (specify) _________________

Internal alternate assessments (specify) __________________


  1. How does this laboratory meet proficiency testing requirements for antifungal susceptibility testing, if performed?

Commercial provider (specify) _________________

Internal alternate assessments (specify) __________________



(changed question number) 

  1. How are results of AFST reported? (select one)

Categorical interpretation only (susceptible, resistant, etc.)

MIC only

Both--categorical interpretation PLUS MIC

Unknown


  1. How are results of AFST reported when breakpoints are available? (select one)

Categorical interpretation only (susceptible, resistant, etc.)

MIC only

Both--categorical interpretation PLUS MIC

Unknown



(changed question wording to specify when breakpoints are available, changed question number) 

  1. If categorical interpretation only, how do you determine the categorical interpretation? (check all that apply)

CLSI M27 S4

CLSI M27 S3

From manufacturer of MIC test

Apply epidemiologic breakpoints

Other ______________________________


(removed question)

New question

  1. How are results of AFST reported when breakpoints aren’t available? (select one)

MIC only

Both--categorical interpretation PLUS MIC

Unknown



(new question)

  1. For what type of Candida isolates is antifungal susceptibility testing (AFST) performed automatically/reflexively? (check all that apply)

Blood isolates

Other normally sterile body site isolates

Other (specify) ______________________ No AFST performed automatically (requires

order from a clinician)

Unknown


  1. For what type of Candida isolates is antifungal susceptibility testing (AFST) performed automatically? (check all that apply)

Blood isolates

Other normally sterile body site isolates

Other (specify) ______________________ No AFST performed automatically (requires

order from a clinician)

Unknown



(changed question wording to remove reflexively, changed question number) 

  1. How is AFST performed for the following Candida spp.?

  1. C. albicans

Performed automatically/reflexively (Go to 21ai)

Performed with a clinician’s order (Go to 21ai)

Not performed


  1. When is AFST performed for the following Candida spp.?

  1. C. albicans

Performed automatically (Go to 27ai)

Performed with a clinician’s order (Go to 27ai)

Not performed



(changed question and response wording, updated skip logic, changed question number) 

  1. Drugs for which AFST is performed automatically/reflexively on C. abicans (check all that apply):

Micafungin

Anidulafungin

Caspofungin

Fluconazole

Voriconazole

Amphotericin B

Other

Unknown


  1. Drugs for which AFST is performed on C. ablicans (check all that apply):

Micafungin

Anidulafungin

Caspofungin

Fluconazole

Voriconazole

Amphotericin B

Other

Unknown



(fixed species misspelling) 

  1. How is AFST performed for the following Candida spp.?

  1. C. glabrata

Performed automatically/reflexively (Go to 21bi)

Performed with a clinician’s order (Go to 21bi)

Not performed


  1. When is AFST performed for the following Candida spp.?

  1. C. glabrata

Performed automatically (Go to 27bi)

Performed with a clinician’s order (Go to 27bi)

Not performed



(changed response wording to remove reflexively, updated skip logic) 

  1. How is AFST performed for the following Candida spp.?

  1. C. parapsilosis

Performed automatically/reflexively (Go to 21ci)

Performed with a clinician’s order (Go to 21ci)

Not performed


  1. When is AFST performed for the following Candida spp.?

  1. C. parapsilosis

Performed automatically (Go to 27ci)

Performed with a clinician’s order (Go to 27ci)

Not performed



(changed response wording to remove reflexively, updated skip logic) 

  1. How is AFST performed for the following Candida spp.?

  1. Other Candida spp.

Performed automatically/reflexively (Go to 21di)

Performed with a clinician’s order (Go to 21di)

Not performed


  1. When is AFST performed for the following Candida spp.?

  1. Other Candida spp.

Performed automatically (Go to 27di)

Performed with a clinician’s order (Go to 27di)

Not performed



(changed response wording to remove reflexively, updated skip logic) 

New question

  1. Is this laboratory tracking susceptibility trends for Candida spp. isolates tested in your lab?

Yes

No

Unknown



(new question)







  1. Invasive Staphylococcus aureus Supplemental Surveillance Officer (Attachment #18)

2021 Survey Question

Changes to the 2021 Survey Question

COVID-19 Impact section

  1. Did COVID-19 response activities delay 2021 iSA surveillance work (e.g., unable to meet iSA deadlines during 2021)?

___ yes ___no


COVID-19 Impact section

  1. Did COVID-19 response activities affect or delay 2022 iSA surveillance work (e.g., unable to meet iSA deadlines during 2022)?

___ yes ___no


CDC Responsibilities section


1. CDC staff are responsive to questions/concerns/emails (e.g., Davina Campbell, Runa Gokhale, Kelly Jackson, Isaac See, and Shirley Zhang).

_______ Strongly agree

_______ Agree

_______ Neutral

_______ Disagree

_______ Strongly disagree


CDC Responsibilities section


1. CDC staff are responsive to questions/concerns/emails (e.g., Holly Biggs, Davina Campbell, Kelly Jackson, Isaac See, and Shirley Zhang).

_______ Strongly agree

_______ Agree

_______ Neutral

_______ Disagree

_______ Strongly disagree



  1. HAIC: Invasive Staphylococcus aureus Laboratory Survey: Use of Nucleic Acid Amplification Testing (NAAT) (Attachment #19)


2022 Survey Question

2023 Survey Question

2b. If yes when did the change occur?

MRSA (i.e., not for MSSA) (Month/year of change) _______/_________

Staphylococcus aureus (i.e., both MRSA and MSSA) (Month/year of change) _______/____________


2a. If yes when did the change occur?

MRSA (i.e., not for MSSA) (Month/year of change) _______/_________

Staphylococcus aureus (i.e., both MRSA and MSSA) (Month/year of change) _______/____________

[Updated question number]

1. Do you routinely set up culture for sterile sites (blood, CSF, bone, etc.) on site (in-house) at your laboratory?

Yes - GO TO Q2 No – GO TO Q3


3. Do you routinely set up culture for sterile sites (blood, CSF, bone, etc.) on site (in-house) at your laboratory?

Yes - GO TO Q4 No – GO TO Q3a

[Updated question number]

1a. [If no] To which laboratory do you send sterile specimens for culture/identification?


3a. [If no] To which laboratory do you send sterile specimens for culture/identification?

[Updated question number]


Question 4 asks about methods for identifying S. aureus or MRSA from a positive sterile site (blood, CSF, bone, etc.) culture.

[Added section header]

3c. [If using any of the above tests on sterile site specimens] Do you still obtain an isolate for S. aureus or MRSA? Yes No - GO to Q4



[question split into two– one for identifying S. aureus via positive sterile site culture and one for identifying S. aureus directly from a sterile site specimen]

4. If a sterile site culture is positive, is sub-culturing to obtain an isolate always performed?

Yes – GO TO Q4b No



5d. Do you still obtain an isolate for S. aureus or MRSA if these tests are used?

Yes – END SURVEY No – END SURVEY

[Question split into two]


4a. [If no] explain/specify reason: ______________________________

[New question]

2. Is S. aureus or MRSA routinely identified via culture-based methods on site (in-house) at your laboratory?

Yes - GO TO Q3 No


[Updated question to document type of culture-based methods used rather than yes/no]

4b. If a sterile site culture is positive, how do you identify it as S. aureus? This includes identifying both on-site (in-house) or at another lab. (Check all that apply)

MALDI-TOF – GO TO 4f

Biochemical tests (e.g., catalase, coagulase) – GO TO 4f

Molecular test – GO TO 4c

Other, specify: _____________________ – GO TO 4f

Do not identify as S. aureus– GO TO Q5

2a. [If no] To which laboratory do you send cultures for S. aureus identification?

____________________________


4c. [If molecular test(s) used] Where is molecular testing from a positive sterile site culture completed?

On-site Send out, please specify lab __________________ - GO TO Q4e

[Updated wording]

3b. Which CIDTs do you use (sterile site sources only, i.e. blood, CSF, pleural fluid, bone, etc.)? Please check all that apply.

FilmArray® Blood Culture Identification Panel..Date started__________

Verigene® Gram-Positive Blood Culture Test…Date started__________

Verigene® Staphylococcus Blood Culture Test…Date started__________

Cepheid Xpert® MRSA/SA BC…Date started__________

BD Geneohm® StaphSR…Date started__________

AdvanDx Staphylococcus QuickFISH blood culture kit…Date started__________

AdvanDx S. aureus/CNS PNA FISH…Date started__________

Alere BinaxNOW® Staphylococcus aureus test…Date started__________

Great Basin Staph ID/R blood culture panel…Date started__________

T2Bacteria® Panel…Date started__________

Accelerate PhenoTest™ BC kit…Date started ________________

iCubate iC-GPC Assay™…Date started ________________

mecA XpressFISH® …Date started ________________

Micacom hemoFISH Masterpanel … Date started ________________

ePlex BCID-GP Panel … Date started ________________

Other, Lab Developed Test (detects MRSA or SA)… Date started ____________________

Other commercial test, Specify_______...Date started__________



[broke into two questions to separate tests that start with a positive culture from those that start with a sterile site specimen. One new response option in 4d]

4d. Which molecular tests do you use (cultures from sterile site sources only, i.e. blood, CSF, pleural fluid, bone, etc.)? Please check all that apply.

FilmArray® Blood Culture Identification Panel..Date started__________

Verigene® Gram-Positive Blood Culture Test…Date started__________

Verigene® Staphylococcus Blood Culture Test…Date started__________

Cepheid Xpert® MRSA/SA BC…Date started__________

BD Geneohm® StaphSR…Date started__________

AdvanDx Staphylococcus QuickFISH blood culture kit…Date started__________

AdvanDx S. aureus/CNS PNA FISH…Date started__________

Alere BinaxNOW® Staphylococcus aureus test…Date started__________

Great Basin Staph ID/R blood culture panel…Date started__________

Accelerate PhenoTest™ BC kit…Date started ________________

iCubate iC-GPC Assay™…Date started ________________

mecA XpressFISH® …Date started ________________

Micacom hemoFISH Masterpanel … Date started ________________

ePlex BCID-GP Panel … Date started ________________

BioFire Blood Culture Identification 2 (BCID2) Panel… Date started ________________

Other, Lab Developed molecular Test (detects MRSA or SA)… Date started ____________________

Other commercial molecular test, Specify_______...Date started__________



5b. Which tests do you use to detect S. aureus directly from a sterile site source without culture? (sterile site sources only, i.e. blood, CSF, pleural fluid, bone, etc.)? Please check all that apply.

T2Bacteria® Panel…Date started__________

Karius TestTM…Date started__________

Other, Lab Developed Test (detects MRSA or SA)… Date started ____________________

Other commercial test, Specify_______...Date started__________


4e. Are positive molecular tests from sterile site cultures appearing in the S. aureus surveillance laboratory line lists? Yes – GO TO Q5

No – GO TO Q5 Unknown – GO TO Q5

[New question]

3d. [If no] Do you plan to start offering any CIDTs for S. aureus or MRSA within the next year?

Yes No – END SURVEY



[Broke into two questions to separate tests that start with a positive culture from those that start with a sterile site specimen]

4f. [If not using molecular tests from sterile site cultures on-site] Do you plan to start offering any molecular tests for detection of S. aureus or MRSA from a positive sterile source culture within the next year? Yes No – GO TO Q3



5e. [If no] Do you plan to start offering any tests for detection of S. aureus or MRSA directly from a sterile source within the next year?

Yes No – END SURVEY

3e. When do you plan to start offering CIDTs?

Month/Year: ____/____



[Broke into two questions to separate tests that start with a positive culture from those that start with a sterile site specimen]

4g. When do you plan to start offering molecular tests?

Month/Year: ____/____



5f. When do you plan to start offering these tests?

Month/Year: ____/____

3f. Where do you plan to have CIDT tested?

On-site Send out, please specify lab __________________ - END SURVEY



[Broke into two questions to separate tests that start with a positive culture from those that start with a sterile site specimen]

4h. Where do you plan to have molecular tests performed?

On-site Send out, please specify lab __________________ - GO TO Q3



5g. Where do you plan to have these tests performed?

On-site Send out, please specify lab __________________ - END SURVEY


Question 5 asks about testing performed directly on sterile site specimens (a positive blood culture is not required to perform these tests).

[Added section header]

3. Do you routinely run any culture independent diagnostic tests (CIDT) on site or at another lab for detection of S. aureus or MRSA either directly from a sterile source (CSF, Blood, etc.) or from a positive blood culture?

Yes No - GO TO Q3d

5. Do you routinely run any tests on site (in-house) or at another lab that detect of S. aureus directly from a sterile source (e.g., blood, CSF) without a culture?

Yes No - GO TO Q5e

[Updated question number. Edited question so it only refers to tests performed directly from a sterile source]

3a. [If yes] Where is CIDT testing completed?

On-site Send out, please specify lab __________________ - GO TO Q3c


5a. [If yes] Where is this testing completed?

On-site Send out, please specify lab __________________ - GO TO Q5e

[Updated question number. Edited question so it only refers to tests performed directly from a sterile source]


5c. Are all positive tests directly from sterile sources appearing in the S. aureus surveillance laboratory line lists?

Yes No Unknown

[New question]

4. How does your lab use the CIDT for detection of S. aureus or MRSA? (select one)

Test concurrently with culture

Reflex to culture after positive by CIDT panel

Only run CIDT panel, no additional testing is done

Other, specify _____________

[Deleted question]



File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorNti-Berko, Sonja Mali (CDC/DDID/NCEZID/DPEI)
File Modified0000-00-00
File Created2024-07-21

© 2024 OMB.report | Privacy Policy